(Q34607338)

3 August 2017

title

Adoption and implementation of medications in addiction treatment programs (English)

1 reference

3 August 2017

Hannah K Knudsen

1

1 reference

3 August 2017

Amanda J Abraham

series ordinal

2

1 reference

3 August 2017

Paul M Roman

series ordinal

3

1 reference

3 August 2017

publication date

1 March 2011

1 reference

Journal of Addiction Medicine

3 August 2017

published in

1 reference

3 August 2017

volume

5

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

21-27

1 reference

Factors determining how early adopter physicians use buprenorphine in treatment

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Counselor attitudes toward pharmacotherapies for alcohol dependence.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Factors affecting willingness to provide buprenorphine treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

State policy influence on the early diffusion of buprenorphine in community treatment programs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Role of state policies in the adoption of naltrexone for substance abuse treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Availability of addiction medications in private health plans

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Client and counselor attitudes toward the use of medications for treatment of opioid dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Trends in the adoption of medications for alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Medications development: successes and challenges

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Adoption of naltrexone to treat alcohol dependence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Racial and ethnic disparities in SSRI availability in substance abuse treatment

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Buprenorphine diffusion: the attitudes of substance abuse treatment counselors

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Modeling the use of innovations in private treatment organizations: the role of absorptive capacity

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Understanding US addiction physicians' low rate of naltrexone prescription

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Research to practice: adoption of naltrexone in alcoholism treatment

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Adoption and implementation of new technologies in substance abuse treatment.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045214

Using stated preference and revealed preference modeling to evaluate prescribing decisions

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21359109

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/ADM.0B013E3181D41DDB

1 reference

3 August 2017

1 reference

3 August 2017

1 reference